In Brief: OncorMed/Endocrine Sciences
This article was originally published in The Gray Sheet
Executive Summary
OncorMed/Endocrine Sciences: Enter two-year distribution agreement, for undisclosed terms, under which Endocrine Sciences will distribute OncorMed's RET gene test for familial medullary thyroid carcinoma. Calabasas Hills, California-based Endocrine Sciences has the only U.S. sales force exclusively focused on selling diagnostic products to endocrinologists, the firm claims. OncorMed will perform the tests, provide client services, technical assistance, sales training and marketing and sales materials...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.